Suppr超能文献

由产β-内酰胺酶、对庆大霉素高度耐药的粪肠球菌引起的感染。

Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis.

作者信息

Wells V D, Wong E S, Murray B E, Coudron P E, Williams D S, Markowitz S M

机构信息

Department of Veterans Affairs Medical Center, Richmond, VA 23249.

出版信息

Ann Intern Med. 1992 Feb 15;116(4):285-92. doi: 10.7326/0003-4819-116-4-285.

Abstract

OBJECTIVE

To investigate the risk factors, clinical features, molecular epidemiology, and treatment outcomes associated with an outbreak of infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis.

DESIGN

Case-control and molecular genetics study.

SETTING

Tertiary care Veterans Affairs hospital.

PATIENTS

Sixty-five patients infected or colonized with beta-lactamase-producing high-level gentamicin-resistant E. faecalis (case patients) were matched and compared with 65 randomly selected patients infected or colonized with beta-lactamase-negative, gentamicin-susceptible E. faecalis.

MEASUREMENTS AND MAIN RESULTS

During the 20-month study period, 124 of 1506 isolates (8.2%) of E. faecalis from 70 patients were found to produce beta-lactamase. Univariate analysis showed older age, higher APACHE II score, nosocomial acquisition, recent surgical procedure, total parenteral nutrition, and antibiotic treatment to be significantly associated with the acquisition of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis. A multivariate analysis, done using stepwise multiple logistic regressions, showed that only two variables remained significant: an APACHE II score greater than 6 (odds ratio, 9.5; 95% CI, 4.4 to 20.3) and antibiotic treatment (odds ratio, 10.2; CI, 4.5 to 23.2). The mortality rate for case patients was 7.7% (5 of 65 patients; CI, 1.2% to 14.2%); no control patient died. Of 23 infections occurring in case patients, 13 were treated with "inappropriate" antibiotics (regimens that included a beta-lactamase-unstable antibiotic); 2 patients improved and 11 had complete resolution of disease. "Appropriate" treatments (regimens that included a beta-lactamase-stable antibiotic) were used in 10 patients; 5 of 10 infections were fatal. Restriction enzyme digests of total chromosomal DNA showed nearly identical patterns for selected isolates of beta-lactamase-producing, high-level gentamicin-resistant E. faecalis, suggesting dissemination through the hospital of a single strain of E. faecalis.

CONCLUSIONS

Fatal infections were observed despite treatment with beta-lactamase-stable antibiotics. The risk for infection or colonization with beta-lactamase-producing, high-level gentamicin-resistant E. faecalis was strongly associated with severe underlying disease (acute physiology and chronic health evaluation [APACHE] II score, greater than 6) and previous antibiotic treatment. These results may be useful in targeting high-risk patients for infection-control interventions.

摘要

目的

调查与产β-内酰胺酶、高水平庆大霉素耐药粪肠球菌感染暴发相关的危险因素、临床特征、分子流行病学及治疗结果。

设计

病例对照和分子遗传学研究。

地点

三级医疗退伍军人事务医院。

患者

65例感染或定植产β-内酰胺酶、高水平庆大霉素耐药粪肠球菌的患者(病例组)与65例随机选择的感染或定植β-内酰胺酶阴性、庆大霉素敏感粪肠球菌的患者进行匹配并比较。

测量指标和主要结果

在20个月的研究期间,70例患者的1506株粪肠球菌分离株中有124株(8.2%)产β-内酰胺酶。单因素分析显示,年龄较大、急性生理与慢性健康状况评分系统(APACHE)II评分较高、医院获得性感染、近期手术、全胃肠外营养和抗生素治疗与产β-内酰胺酶、高水平庆大霉素耐药粪肠球菌的获得显著相关。使用逐步多元逻辑回归进行的多因素分析显示,只有两个变量仍然显著:APACHE II评分大于6(比值比,9.5;95%可信区间,4.4至20.3)和抗生素治疗(比值比,10.2;可信区间,4.5至23.2)。病例组患者的死亡率为7.7%(65例患者中有5例;可信区间,1.2%至14.2%);对照组患者无死亡。病例组发生的23例感染中,13例接受了“不适当”的抗生素治疗(包括β-内酰胺酶不稳定抗生素的治疗方案);2例患者病情改善,11例患者疾病完全缓解。10例患者采用了“适当”的治疗(包括β-内酰胺酶稳定抗生素的治疗方案);10例感染中有5例死亡。对产β-内酰胺酶、高水平庆大霉素耐药粪肠球菌的选定分离株进行的总染色体DNA限制性酶切分析显示,其模式几乎相同,提示单一粪肠球菌菌株在医院内传播。

结论

尽管使用了β-内酰胺酶稳定抗生素治疗,但仍观察到致命感染。产β-内酰胺酶、高水平庆大霉素耐药粪肠球菌感染或定植的风险与严重基础疾病(急性生理与慢性健康状况评分系统[APACHE]II评分大于6)和既往抗生素治疗密切相关。这些结果可能有助于针对高危患者采取感染控制干预措施。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验